Inhibitory effects of the sustained delivery systems (microcapsules and microgranules) of a potent antagonist of luteinizing hormone-releasing hormone N-Ac- on the growth of experimental prostate cancers were investigated. In the first experiment, three doses of a microcapsule preparation releasing 23.8, 47.6, and 71.4 Although androgen deprivation represents standard treatment for prostatic cancer, new approaches are constantly explored to improve the therapy in terms of response rates, duration of response, and increase in survival rate (1, 2). Since the isolation and structural elucidation of hypothalamic luteinizing hormone-releasing hormone (LH-RH), more than 3000 analogs were synthesized in view of their potential medical applications (3, 4) . The inhibition of the pituitarygonadal axis by chronic administration of LH-RH agonistic analogs, including LH-RH, shown in animals (5) and man (6), led to demonstration of the suppression of growth of prostate tumors in animals (7) and their successful use in the treatment of prostatic cancer in patients (8) as a better alternative to castration or estrogens (1, 3). Although repeated administration of LH-RH agonists is required to inhibit luteinizing hormone (LH) release and reduce the levels of sex steroids, similar effects can be obtained with a single dose of LH-RH antagonists (1, 3, 4). The antagonistic analogs were synthesized initially for use in gynecology as contraceptives (1, 3). However, progress in development and clinichl application of LH-RH antagonists has been slow (1). High-dose requirements, due to low potency of earlier compounds and side effects related to histamine release of analogs with D-arginine in position 6, delayed clinical use of LH-RH antagonists (1, 4, 9) .
days for controls. The body weights were unchanged. The weights of testes, seminal vesicles, and ventral prostate were greatly reduced in all three groups that received SB-75, and testosterone levels were decreased to nondetectable values in the case of the two higher doses of SB-75. LH levels were also diminished. Similar results were obtained in the second experiment, in which the animals were treated for a period of 8 weeks with microgranules of SB-75. Therapy with microgranules of SB-75 significantly decreased tumor growth as measured by the final tumor volume, the percentage change from the initial tumor volume, and the reduction in tumor weight. The results indicate that antagonist SB-75, released from sustained delivery systems, can produce a state of chemical castration and effectively inhibit the growth of experimental prostate cancers. The efficacy of the antagonist SB-75 in inhibiting androgendependent Dunning prostatic carcinoma and the absence of side effects suggest its possible usefulness for the treatment of hormone-sensitive tumors.
Although androgen deprivation represents standard treatment for prostatic cancer, new approaches are constantly explored to improve the therapy in terms of response rates, duration of response, and increase in survival rate (1, 2) . Since the isolation and structural elucidation of hypothalamic luteinizing hormone-releasing hormone (LH-RH), more than 3000 analogs were synthesized in view of their potential medical applications (3, 4) . The inhibition of the pituitarygonadal axis by chronic administration of LH-RH agonistic analogs, including [D-Trp6]LH-RH, shown in animals (5) and man (6), led to demonstration of the suppression of growth of prostate tumors in animals (7) and their successful use in the treatment of prostatic cancer in patients (8) as a better alternative to castration or estrogens (1, 3) . Although repeated administration of LH-RH agonists is required to inhibit luteinizing hormone (LH) release and reduce the levels of sex steroids, similar effects can be obtained with a single dose of LH-RH antagonists (1, 3, 4) . The antagonistic analogs were synthesized initially for use in gynecology as contraceptives (1, 3) . However, progress in development and clinichl application of LH-RH antagonists has been slow (1). High-dose requirements, due to low potency of earlier compounds and side effects related to histamine release of analogs with D-arginine in position 6, delayed clinical use of LH-RH antagonists (1, 4, 9) .
Modem LH-RH antagonists, free of edematogenic and anaphylactoid reactions, containing neutral hydrophilic D-ureidoalkyl amino acids such as D-citrulline and D-homocitrulline at position 6, were recently synthesized in our laboratory and tested in vitro and in vivo (10) (11) (12) . Among these analogs,
RH; SB-75} was shown to be one of the most powerful antagonists in blocking ovulation and inhibiting LH levels in rats (9, 11, 12) . The use of antagonists in tumor therapy would avoid the transient stimulation that occurs initially in response to LH-RH agonists and prevent the temporary clinical "flareup" of the disease.
Further improvement in the convenience and reliability of treatment could be achieved by the use of long-acting delivery systems for controlled release of peptides (1, 3, (12) (13) (14) (15) (13, 14) . These systems are based on microcapsules or microgranules of polymers of DL-lactide-coglycolide, which are biodegradable and compatible with living tissues (12, 13, 15) . We have demonstrated the efficacy of formulations of microcapsules of the agonist [D-Trp6]LH-RH experimentally (13, (16) (17) (18) and clinically (1, 3, 19) . Prototypes of microcapsules of somatostatin analog RC-160 and, more recently, of LH-RH antagonist SB-75 were also used in the treatment of experimental breast cancer and pancreatic cancer (20, 21 
was synthesized by solid-phase methods in our laboratory (11) . Bulk amounts of SB-75 were prepared according to the same methods by Asta Pharma (Frankfurt/Main) for microencapsulation. This product was identical with our preparation, physicochemically (HPLC, IR spectrum) and biologically in vitro and in vivo (9, 12) . SB-75 microcapsules were prepared by P. Orsolini, Cytotech, using a phase separation process and sterilized by y-irradiation. The product was a free-flowing powder of nearly spherical particles consisting of 2% (wt/wt) SB-75 trifluoroacetate in a polymeric matrix of poly(DLlactide-coglycolide) (12) . Three batches (lot nos. RCS 0003, 0004, and 0005) were used in this study.
SB-75 pamoate microgranules (prototype lot RGS 9002) were also prepared by P. Orsolini (Cytotech) as described (15) and consisted of SB-75 pamoate [4.5% (wt/wt)] distributed within a polymer matrix of poly(DL-lactide-coglycolide). For injection, the microgranules were suspended in 0.7 ml of injection vehicle consisting of2% CM-cellulose and 1% Tween 80 in water. The suspension was mixed thoroughly on a Vortex mixer and injected i.m. through an 18-gauge needle.
In the first experiment, 19 After 8 weeks of treatment, rats were sacrificed by decapitation and trunk blood was collected. The blood was centrifuged and serum was preserved for hormone studies. Various organs (testicles, seminal vesicles, ventral prostates) were removed, cleaned, weighed, and preserved for pathological studies, which will be reported elsewhere (24) . Pituitary glands were removed and frozen at -800C for receptor studies described elsewhere (25) . Tumors were carefully cleaned and weighed, and then a sample was taken for histological studies and the rest was stored at -80'C for receptor studies (25) .
Serum levels of hormones were measured by doubleantibody RIAs using materials supplied by the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases, as described (12, 16) . The results are expressed in terms of ng of Rat-LH-RP-3, Rat-GH-RP-2, Rat-FSH-RP-2, and Rat-Prl-RP-3 standards per ml. Serum testosterone was measured by RIA using kits obtained from Diagnostic Products, Los Angeles (9) .
All data are expressed as the mean ± SEM and statistical analyses were performed by using a computer-assisted program and Duncan's new multiple-range test (26 cally and biochemically similar to human tumors. Its hormonal dependency makes it also suitable for testing hormonal manipulations, including the use of LH-RH analogs (1, 7, 13, 16-18, 22, 23) . We have previously shown that chronic administration of agonist [D-Trp6]LH-RH or older antagonists of LH-RH to Copenhagen rats bearing the Dunning R-3327 carcinoma inhibited tumor growth and decreased the levels of testosterone, LH, FSH, the weight of prostate, seminal vesicles, and testicles (1, 7, 13, 16-18, 22, 23) . The present study, using sustained-release microcapsules and microgranules ofthe modem antagonist SB-75, extends these findings. The sustained-delivery systems are more convenient and more efficacious for delivering therapeutic doses of agonists and antagonists than multiple daily administration (12) . Clinical use of sustained-release formulation of agonists of LH-RH was previously shown to be efficacious (19) . The suppression of gonadal functions achieved by administration of LH-RH agonists and antagonists is equivalent to chemical castration and provides an efficient approach for the treatment of prostate cancer and other sex hormone-dependent tumors (1, 3, 16, 20, 21 (20) . In breast cancer, as in prostate cancer, the advantage of antagonists, in addition to a possible better inhibition of tumor growth, could be also based on the fact that they inhibit LH, FSH, and sex steroid secretions 24 from the start of the administration. The use of antagonists in the treatment of cancer would avoid the transient stimulation of the release of gonadotropins and sex steroids that occurs initially in response to LH-RH agonists (1, 3, 10, 11, 20) . The antagonist SB-75 was also demonstrated to inhibit tumor growth and promote programed cell death (apoptosis) in N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancers in hamsters (27) .
The inhibition of LH, FSH, and testosterone levels in men by antagonistic analog SB-75 was recently shown by our group.t Preliminary results during its administration in patients with advanced prostatic carcinoma show improvement of clinical signs and symptoms with no accompanying side effects.A Direct effects of modem antagonistic analogs, such as SB-75, on tumors should be explored, since the existence of receptors for LH-RH was demonstrated in Dunning prostate tumors and other tumors in animals (1, 3, 28, 29) and in human prostate cancer (29, 30) . These receptors were characterized and their possible role in mediating direct effects of LH-RH analogs on tumors was suggested (29, 30) . Direct inhibition of growth of estrogen-independent MDA-MB-231 human mammary tumor cell line by antagonists of LH-RH was demonstrated in vitro (31 (16) , the combination treatment of LH-RH antagonist SB-75 with RC-160 should be also explored in prostate cancer models.
The combination of chemotherapy and hormonal manipulation with LH-RH agonists or antagonists (1, 17, 18) or castration (2) is feasible and encouraging in producing a potential cure in hormone-sensitive cancers (2) . The efficacy of combined treatment is greater than that of either agent alone (17, 18) and can be increased by proper timing early in the evolution of cancer (32) . Another approach to a potential cure could consist of use of LH-RH analogs carrying cytotoxic radicals (33, 34) , which could be targeted to prostate and other cancers that have membrane receptors for LH-RH.
In conclusion, our results may provide a stimulus for further studies with LH-RH antagonists in prostate cancer. reported herein represented only prototype batches, our work indicates that the improved sustained delivery formulations of the LH-RH antagonist SB-75 should be capable of maintaining a therapeutic level of the peptide for several weeks. Further work can lead to clinical batches of SB-75 microcapsules or microgranules suitable for the therapy of hormone-sensitive tumors and endocrine and gynecologic disorders.
